Hydroxychloroquine For Prophylaxis Of COVID-19 In Health Workers: A Randomized Clinical Trial
Jorge Rojas-Serrano, Angelica Margarita Portillo-Vásquez Thirion-Romero, Joel Vázquez-Pérez, Fidencio Mejía-Nepomuceno Alejandra Ramírez-Venegas, Karla Midori Pérez-Kawabe, Rogelio Pérez-Padilla
doi:10.1101/2021.05.14.21257059
Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of COVID19 in health personnel exposed to patients infected by SARS-COV-2. Methods: Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVD19 patients. Main outcome was time to symptomatic SARS-CoV2 infection. Results: 127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial, 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9,2%) subjects in the placebo group developed COVID-19. (Log Rank test p = 0.09). No severe COVID19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19.
CONCLUSION Although the number of symptomatic infections in health personnel was lower in the HCQ group, the difference was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size.
Hydroxychloroquine For Prophylaxis Of COVID-19 In Health
SUMMARY Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of COVID19 in health personnel exposed to infected by SARS-COV-2. Methods: Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVD19 patients. Main outcome was time to symptomatic SARS-CoV2 infection. Results: 127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial, 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9,2%) subjects in the placebo group developed COVID-19. (Log Rank test p = 0.09). No severe COVID19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19.
CONCLUSION Although the number of symptomatic infections in health personnel was lower in the HCQ group, the difference was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size. Key words: COVID-19, health workers, prophylaxis, hydroxychloroquine,
References
Bandyopadhyay, Baticulon, Kadhum, Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review, BMJ Glob Heal,
doi:10.1136/bmjgh-2020-003097Booth, Bruno, Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis, Published,
doi:10.1371/journal.pone.0247461Colaneri, Novelli, Cutti, The experience of the health care workers of a severely hit SARS-CoV-2 referral Hospital in Italy: incidence, clinical course and modifiable risk factors for COVID-19 infection, J Public Health,
doi:10.1093/pubmed/fdaa195Dy, Rabajante, A COVID-19 infection risk model for frontline health care workers, Netw Model Anal Heal Informatics Bioinforma,
doi:10.1007/s13721-020-00258-3Furst, Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases, Lupus
Gohar, Larivière, Nowrouzi-Kia, Sickness absence in healthcare workers during the COVID-19 pandemic, Occup Med (Chic Ill),
doi:10.1093/occmed/kqaa093Horby, Mafham, Linsell, Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2022926Id, Chaudhuri, Id, The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials, Published,
doi:10.1371/journal.pone.0244778Indre, Para, Para, EL DIAGNÓSTICO DE SARS-CoV-2 DURANTE LA CONTINGENCIA DE COVID-19 EN MÉXICO,
doi:10.2807/1560Mehra, Desai, Ruschitzka, Patel, RETRACTED:Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet. Published online,
doi:10.1016/S0140-6736(20)31180-6Mehta, Bhandari, Mehta, Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?, J Glob Antimicrob Resist,
doi:10.1016/j.jgar.2020.07.022Nicol, Joshi, Rizk, Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection, Clin Pharmacol Ther. Published online,
doi:10.1002/cpt.1993Oliver, Gargano, Marin, The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine -United States, December 2020, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm6950e2Peder, Id, Wiberg, A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment, Published,
doi:10.1371/journal.pone.0237903Rosenberg, Dufort, Udo, Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State, JAMA -J Am Med Assoc,
doi:10.1001/jama.2020.8630Schulz, Altman, Moher, Consort, Statement: Updated guidelines for reporting parallel group randomised trials, BMJ,
doi:10.1136/bmj.c332Singh, Ryan, Kredo, Chaplin, Fletcher, Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19, Cochrane Database Syst Rev. Published online,
doi:10.1002/14651858.cd013587.pub2Wang, Zhou, Liu, Reasons for healthcare workers becoming infected with novel coronavirus disease 2019 (COVID-19) in China, J Hosp Infect,
doi:10.1016/j.jhin.2020.03.002Wei J Te, Liu, Fan, Zhao, Cao, Epidemiology of and risk factors for COVID-19 infection among health care workers: A multi-centre comparative study, Int J Environ Res Public Health,
doi:10.3390/ijerph17197149White, Watson, Hoglund, Chan, Cheah et al., COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology, PLoS Med,
doi:10.1371/journal.pmed.1003252
